Karydas Daphne (CIK 1816952) reported 10 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-17). Recent activity: Buy MLYS (3,000 shares), Sell MLYS (3,000 shares), Buy MLYS (3,000 shares), Sell MLYS (3,000 shares), Buy MLYS (3,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Mineralys Therapeutics, Inc. (MLYS) | Director | Buy | 3,000 | $36,060 |
| 2026-09-17 | Mineralys Therapeutics, Inc. (MLYS) | Director | Sell | 3,000 | $85,740 |
| 2026-06-17 | Mineralys Therapeutics, Inc. (MLYS) | Director | Buy | 3,000 | $36,060 |
| 2026-06-17 | Mineralys Therapeutics, Inc. (MLYS) | Director | Sell | 3,000 | $75,000 |
| 2026-04-02 | Mineralys Therapeutics, Inc. (MLYS) | Director | Buy | 3,000 | $36,060 |
| 2026-04-02 | Mineralys Therapeutics, Inc. (MLYS) | Director | Sell | 3,000 | $75,000 |
| 2026-02-20 | Mineralys Therapeutics, Inc. (MLYS) | Director | Buy | 6,200 | $0 |
| 2025-11-13 | Mineralys Therapeutics, Inc. (MLYS) | Director | Buy | 15,000 | $153,000 |
| 2025-11-13 | Mineralys Therapeutics, Inc. (MLYS) | Director | Sell | 10,115 | $463,368 |
| 2025-11-13 | Mineralys Therapeutics, Inc. (MLYS) | Director | Sell | 4,885 | $226,469 |
来源：SEC Form 4 申报文件 · 截至 2026-09-17